Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
McKesson
Johnson and Johnson
Colorcon
Harvard Business School

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

AVASTIN Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Recent Clinical Trials for AVASTIN

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Fourth Military Medical UniversityPhase 2/Phase 3
Anne NoonanPhase 1
University of Texas Southwestern Medical CenterPhase 2

See all AVASTIN clinical trials

Recent Litigation for AVASTIN

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
Genentech, Inc. v. Pfizer Inc.2019-04-05
Genentech, Inc. v. Immunex Rhode Island Corp.2019-03-29

See all AVASTIN litigation

PTAB Litigation
PetitionerDate
Forty Seven, Inc.2018-01-08
Pfizer Inc.2018-01-05
Hospira, Inc.2016-09-09

See all AVASTIN litigation

Company Disclosures: US Patents for AVASTIN

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Athena Neurosciences, Inc. (South San Francisco, CA) 2014-01-25 RX Orphan company
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Biogen, Inc. (Cambridge, MA) 2020-08-05 RX Orphan company
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Athena Neurosciences, Inc. (South San Francisco, CA) 2014-01-25 RX Orphan company
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Biogen, Inc. (Cambridge, MA) 2020-08-05 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for AVASTIN

These patents were identified by searching patent claims

Supplementary Protection Certificates for AVASTIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
SZ 23/2006 Austria   Start Trial PRODUCT NAME: NATALIZUMAB
300673 Netherlands   Start Trial PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
300822 Netherlands   Start Trial PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
CA 2016 00031 Denmark   Start Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
CA 2014 00034 Denmark   Start Trial PRODUCT NAME: PACLITAXEL FORMULERET SOM ALBUMINBUNDNE NANOPARTIKLER; REG. NO/DATE: C(2013)9835 20131220
1590004-6 Sweden   Start Trial PRODUCT NAME: POMALIDOMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS, SOLVATES, HYDRATES OR STEREOISOMERS THEREOF; REG. NO/DATE: EU/1/13/850 20130808
PA2014022 Lithuania   Start Trial PRODUCT NAME: PACLITAXELUM; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.